Cargando…

Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs

PURPOSE: The present study aimed to evaluate the incidence rate of radiation pneumonitis (RP) in patients with advanced lung adenocarcinoma treated with first-generation (1G), second-generation (2G), or third-generation (3G) epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mu, Fengchun, Fan, Bingjie, Li, Butuo, Qin, Wenru, Li, Haoqian, Wang, Chunni, Zou, Bing, Wang, Shijiang, Wang, Linlin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106805/ https://www.ncbi.nlm.nih.gov/pubmed/37077536 http://dx.doi.org/10.2147/CMAR.S404874

Ejemplares similares

Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous EGFR-TKI and thoracic radiotherapy
por: Jia, Wenxiao, et al.
Publicado: (2021)

Symptomatic Radiation Pneumonitis in NSCLC Patients Receiving EGFR-TKIs and Concurrent Once-daily Thoracic Radiotherapy: Predicting the Value of Clinical and Dose-volume Histogram Parameters
por: YANG, Xuexi, et al.
Publicado: (2022)

Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer
por: Qin, Wenru, et al.
Publicado: (2022)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017)

Integrated multi-dimensional deep neural network model improves prognosis prediction of advanced NSCLC patients receiving bevacizumab
por: Li, Butuo, et al.
Publicado: (2023)

Multiple Immune Features-Based Signature for Predicting Recurrence and Survival of Inoperable LA-NSCLC Patients
por: Guo, Meiying, et al.
Publicado: (2020)

Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients
por: Yan, Han, et al.
Publicado: (2015)

Pulmonary sarcoidosis-like reactions induced by sintilimab in esophageal cancer: A case report
por: Li, Haoqian, et al.
Publicado: (2023)

Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis
por: Chen, Yanxin, et al.
Publicado: (2019)

Evaluating the Efficacy of EGFR-TKIs Combined With Radiotherapy in Advanced Lung Adenocarcinoma Patients With EGFR Mutation: A Retrospective Study
por: Wang, Yuxiang, et al.
Publicado: (2022)

Transformation from Small Cell to Squamous Cell Carcinoma in a Thymic Carcinoma Patient with a Durable Response to Anlotinib: A Case Report
por: Qin, Wenru, et al.
Publicado: (2022)

Prophylactic cranial irradiation-related lymphopenia affects survival in patients with limited-stage small cell lung cancer
por: Fan, Xinyu, et al.
Publicado: (2023)

The role of procalcitonin in differential diagnosis between acute radiation pneumonitis and bacterial pneumonia in lung cancer patients receiving thoracic radiotherapy
por: Wang, Zhiwu, et al.
Publicado: (2020)

Radiation recall pneumonitis induced by chemotherapy after thoracic radiotherapy for lung cancer
por: Ding, Xiao, et al.
Publicado: (2011)

Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review
por: Li, Butuo, et al.
Publicado: (2021)

Effect of EGFR-TKIs combined with craniocerebral radiotherapy on the prognosis of EGFR-mutant lung adenocarcinoma patients with brain metastasis: A propensity-score matched analysis
por: Deng, Guangchuan, et al.
Publicado: (2023)

Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer
por: Lu, Xiaotong, et al.
Publicado: (2022)

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs
por: Zhang, Chengjuan, et al.
Publicado: (2017)

Therapeutic Effect Of First-Line EGFR-TKIs Combined With Concurrent Cranial Radiotherapy On NSCLC Patients With EGFR Activating Mutation And Brain Metastasis: A Retrospective Study
por: An, Ning, et al.
Publicado: (2019)

EGFR-TKIs resistance via EGFR-independent signaling pathways
por: Liu, Qian, et al.
Publicado: (2018)

High-G Calibration Denoising Method for High-G MEMS Accelerometer Based on EMD and Wavelet Threshold
por: Lu, Qing, et al.
Publicado: (2019)

Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases
por: Saida, Yu, et al.
Publicado: (2019)

Role of GPER1 in the Mechanism of EGFR-TKIs Resistance in Lung Adenocarcinoma
por: Li, Zhenhua, et al.
Publicado: (2022)

Epigenetic suppression of EGFR signaling in G-CIMP+ glioblastomas
por: Li, Jie, et al.
Publicado: (2014)

The Versatile Functions of G. Lucidum Polysaccharides and G. Lucidum Triterpenes in Cancer Radiotherapy and Chemotherapy
por: Xu, Jing, et al.
Publicado: (2021)

EGFR G796D mutation mediates resistance to osimertinib
por: Zheng, Di, et al.
Publicado: (2017)

Three models that predict the efficacy of immunotherapy in Chinese patients with advanced non‐small cell lung cancer
por: Zhao, Qian, et al.
Publicado: (2021)

A novel deep learning prognostic system improves survival predictions for stage III non‐small cell lung cancer
por: Yang, Linlin, et al.
Publicado: (2022)

Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma
por: Li, Qiwen, et al.
Publicado: (2021)

Efficacy and Safety of Radiotherapy Plus EGFR-TKIs in NSCLC Patients with Brain Metastases: A Meta-Analysis of Published Data
por: Wang, Xueyan, et al.
Publicado: (2018)

Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib
por: Smith, Clayton P., et al.
Publicado: (2023)

Performance Evaluation of MPTCP on Simultaneous Use of 5G and 4G Networks
por: Mahmud, Imtiaz, et al.
Publicado: (2022)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

Making the Best Use of Available Weapons for the Inevitable Rivalry-Resistance to EGFR-TKIs
por: Li, Dongyu, et al.
Publicado: (2023)

The influence of tumor heterogeneity on sensitivity of EGFR-mutant lung adenocarcinoma cells to EGFR-TKIs
por: Sun, Li, et al.
Publicado: (2019)

Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
por: Xiong, Liwen, et al.
Publicado: (2017)

PAI-1 4G/5G Polymorphism Contributes to Cancer Susceptibility: Evidence from Meta-Analysis
por: Wang, Shangqian, et al.
Publicado: (2013)

Survival benefit of thoracic radiotherapy plus EGFR-TKIs in patients with non-oligometastatic advanced non-small-cell lung cancer: a single-center retrospective study
por: Zhou, Fangyuan, et al.
Publicado: (2023)

The Kinetic Changes of Systemic Inflammatory Factors during Bevacizumab Treatment and Its Prognostic Role in Advanced Non-small Cell Lung Cancer Patients
por: Li, Butuo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_304pd8s54pglobvsk0l0am87ec